Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder
Authors:
- 25 December 2020
- journal article
- research article
- Published by Wiley in Bipolar Disorders
- Vol. 23 (6) , 595-603
Abstract
Objectives: Endoxifen is a protein kinase C inhibitor. The objective of the present phase III study was to demonstrate the safety and efficacy of endoxifen in treating bipolar I disorder (BPD I) patients.Methods: A multicenter, double‐blind, active‐controlled study was conducted using a daily dose of 8 mg endoxifen compared to 1000 mg divalproex, the current standard treatment, in patients with BPD I acute manic episodes with/without mixed features. The primary endpoint of our study was the mean change in total Young Mania Rating Scale (YMRS) score at day 21.Results: Endoxifen (n = 116) significantly (p < 0.0001) reduced total YMRS score (from 33.1 to 17.8. A significant (p < 0.001) improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) score was observed for endoxifen (4.8 to 2.5). Early time to remission of the disease was observed with endoxifen compared to divalproex. None of the patients required rescue medication and there was no drug‐associated withdrawals. Changes in Clinical Global Impressions‐Bipolar Disorder and Clinical Global Impression‐Severity of Illness scores showed that treatment with endoxifen was well‐tolerated.Conclusions: Endoxifen at a low daily dose of 8 mg was as efficacious and safe in patients with BPD I acute manic episodes with/without mixed features.Keywords
This publication has 45 references indexed in Scilit:
- Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar maniaJournal of Affective Disorders, 2011
- Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled studyJournal of Affective Disorders, 2011
- Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled TrialsNeuropsychopharmacology, 2010
- Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorderBioorganic & Medicinal Chemistry Letters, 2010
- Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute maniaJournal of Affective Disorders, 2007
- The armamentarium of treatments for bipolar disorder: a review of the literatureInternational Journal of Neuropsychopharmacology, 2006
- Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidolEuropean Neuropsychopharmacology, 2005
- “It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphismLife Sciences, 1995
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978